Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study
Background and objective: Nesfatin-1 is a newly described peptide, derived from nucleobindin2. Nesfatin-1 suppresses food intake and it is involved in regulating insulin secretion. The aim of this study was to compare serum levels of Nesfatin-1 in patients having type 2 diabetes and non-diabetic sub...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Hawler Medical University
2020-06-01
|
| Series: | Zanco Journal of Medical Sciences |
| Subjects: | |
| Online Access: | https://zjms.hmu.edu.krd/index.php/zjms/article/view/716/615 |
| _version_ | 1828298009940590592 |
|---|---|
| author | Niyan Jassim Mohammad Dler Qader Gallaly |
| author_facet | Niyan Jassim Mohammad Dler Qader Gallaly |
| author_sort | Niyan Jassim Mohammad |
| collection | DOAJ |
| description | Background and objective: Nesfatin-1 is a newly described peptide, derived from nucleobindin2. Nesfatin-1 suppresses food intake and it is involved in regulating insulin secretion. The aim of this study was to compare serum levels of Nesfatin-1 in patients having type 2 diabetes and non-diabetic subjects.
Methods: This cross-sectional study included 90 participants; 64 patients with type 2 diabetes mellitus (32 males and 32 females) and 26 control subjects (13 males and 13 female). Body mass index, fasting serum level of glucose, fasting serum level of insulin, and glycated hemoglobin were estimated. Homeostasis model assessment of insulin resistance was calculated. Nesfatin-1 level was measured using enzyme-linked immune-sorbent assay kit. The data was analyzed using Graphpad prism 7.04 for windows.
Results: Type 2 diabetes patients aged from 33-78 years and the control group aged from 32-75 years. Nesfatin-1 level in the diabetic group was significantly lower than controls. The median interquartile range (IQR) of Nesfatin-1 was 0.765 (0.4-1.173) in diabetes and 1.02 (0.775-1.458) in controls. The diabetes group has significantly higher homeostasis model assessment of insulin resistance compared with non-diabetics. Serum Nesfatin-1 was correlated negatively with body mass index, fasting serum glucose, fasting serum insulin, glycatedhemoglobin, and homeostasis assessment of insulin resistance.
Conclusion: Serum Nesfatin-1 level is negatively correlated with fasting serum glucose, fasting serum insulin, and glycated hemoglobin. This association supports the role of Nesfatin-1 in increased insulin resistance in patients with type 2 diabetes. |
| first_indexed | 2024-04-13T12:34:03Z |
| format | Article |
| id | doaj.art-f753f9bec088485497ebbbf81f125724 |
| institution | Directory Open Access Journal |
| issn | 1995-5588 1995-5596 |
| language | English |
| last_indexed | 2024-04-13T12:34:03Z |
| publishDate | 2020-06-01 |
| publisher | Hawler Medical University |
| record_format | Article |
| series | Zanco Journal of Medical Sciences |
| spelling | doaj.art-f753f9bec088485497ebbbf81f1257242022-12-22T02:46:43ZengHawler Medical UniversityZanco Journal of Medical Sciences1995-55881995-55962020-06-012411710.15218/zjms.2020.001Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional studyNiyan Jassim Mohammad0Dler Qader Gallaly 1Hawler Medical UniversityHawler Medical UniversityBackground and objective: Nesfatin-1 is a newly described peptide, derived from nucleobindin2. Nesfatin-1 suppresses food intake and it is involved in regulating insulin secretion. The aim of this study was to compare serum levels of Nesfatin-1 in patients having type 2 diabetes and non-diabetic subjects. Methods: This cross-sectional study included 90 participants; 64 patients with type 2 diabetes mellitus (32 males and 32 females) and 26 control subjects (13 males and 13 female). Body mass index, fasting serum level of glucose, fasting serum level of insulin, and glycated hemoglobin were estimated. Homeostasis model assessment of insulin resistance was calculated. Nesfatin-1 level was measured using enzyme-linked immune-sorbent assay kit. The data was analyzed using Graphpad prism 7.04 for windows. Results: Type 2 diabetes patients aged from 33-78 years and the control group aged from 32-75 years. Nesfatin-1 level in the diabetic group was significantly lower than controls. The median interquartile range (IQR) of Nesfatin-1 was 0.765 (0.4-1.173) in diabetes and 1.02 (0.775-1.458) in controls. The diabetes group has significantly higher homeostasis model assessment of insulin resistance compared with non-diabetics. Serum Nesfatin-1 was correlated negatively with body mass index, fasting serum glucose, fasting serum insulin, glycatedhemoglobin, and homeostasis assessment of insulin resistance. Conclusion: Serum Nesfatin-1 level is negatively correlated with fasting serum glucose, fasting serum insulin, and glycated hemoglobin. This association supports the role of Nesfatin-1 in increased insulin resistance in patients with type 2 diabetes.https://zjms.hmu.edu.krd/index.php/zjms/article/view/716/615type 2 diabetes mellitusnesfatin-1homeostasis model assessment of insulin resistanceglycated hemoglobin |
| spellingShingle | Niyan Jassim Mohammad Dler Qader Gallaly Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study Zanco Journal of Medical Sciences type 2 diabetes mellitus nesfatin-1 homeostasis model assessment of insulin resistance glycated hemoglobin |
| title | Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study |
| title_full | Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study |
| title_fullStr | Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study |
| title_full_unstemmed | Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study |
| title_short | Serum Nesfatin-1 in patients with type 2 diabetes mellitus: A cross sectional study |
| title_sort | serum nesfatin 1 in patients with type 2 diabetes mellitus a cross sectional study |
| topic | type 2 diabetes mellitus nesfatin-1 homeostasis model assessment of insulin resistance glycated hemoglobin |
| url | https://zjms.hmu.edu.krd/index.php/zjms/article/view/716/615 |
| work_keys_str_mv | AT niyanjassimmohammad serumnesfatin1inpatientswithtype2diabetesmellitusacrosssectionalstudy AT dlerqadergallaly serumnesfatin1inpatientswithtype2diabetesmellitusacrosssectionalstudy |